
TELOCYTE
A FUTURE BEYOND ALZHEIMER'S
A future beyond Alzheimer's
Telocyte™ seeks to cure age-related disease, starting with Alzheimer's

Legal Disclaimer

The content of this presentation is proprietary and confidential information of Telocyte LLC. It is not intended to be distributed to any third party without the written consent of Telocyte LLC.

Each person who has received a copy of this presentation is deemed to have agreed to not reproduce or distribute this presentation, in whole or in part, without the prior written consent of Telocyte LLC.

2

Age-related Diseases: A Global Crisis

Governments

"Public health expenditure in EU may grow to 7.7 % of GDP in 2070 only on accounts of demographic ageing"
(European Commision, 2021 Ageing Report[1])



Sovereign Wealth

Hevolution Foundation: $1 billion annually to fight aging and age-related diseases

"There is not a bigger medical problem on the planet than this one."
(Mehmood Khan, Fund Manager[2])

Most Successful Entrepreneurs

Jeff Bezos and Yuri Milner: $3 billion pledged to Altos Labs for cell rejuvenation and fight aging[3]

Larry Page: $1.5 billion for Google's anti-aging California Life Company[4]

Larry Ellison and Peter Thiel: $1 billion for age-related disease and sustainability[5]

[1]https://ec.europa.eu/info/sites/default/files/economy-finance/ip148_en.pdf
[2]https://www.technologyreview.com/2022/06/07/1053132/saudi-arabia-slow-aging-metformin/
[3]https://www.ns-healthcare.com/news/altos-labs-launches-with-3bn-funding/
[4]https://www.technologyreview.com/2016/12/15/69305/googles-long-strange-life-span-trip/
[5]https://www.breakoutlabs.org/

In Focus: Alzheimer's Disease

An age-related disease with no cure

A leading cause of death in adults, about **500,000 per year**[1]

Affects 1**0% over 65** and **50% over 85** in the US[2]

The global numbers have more than doubled from **1990 to 2016**[2]

The costliest disease for adults averaging over **$52k/year/adult**[2]

[1]https://www.usagainstalzheimers.org/alzheimers-disease-get-facts
[2]https://curealz.org/the-disease/stats-and-costs/

Failures

NIH: $16 billion

NIH spent over $16 billion on Alzheimer's drug solutions since 2008. **All have failed**[1]

Biogen $28 billion drug debacle

Biogen's disregard of **FDA's decision NOT to endorse the company's Alzheimer's drug Aduhelm** in 2021 compelled the FDA to call for an investigation.

"We have spent more than $28 billion in R&D since 2003" (Biogen CEO,2021)[3]

Merck's drug failures

No significant new drug for Alzheimer's has been approved in the past 20 years, despite massively expensive trials[2]

Roche Group drug failure

A decade-long clinical trial of a potential Alzheimer's drug failed to prevent or slow cognitive decline, another disappointment in the effort to find solutions for the disease[4]

99.6% failure rate

A graveyard for drugs: **1 out of 244 drugs for Alzheimer's disease was approved in 2002-2012**, a 99.6% failure rate[5]

$42.5B since '95

Over 2,200 clinical trials, with no cure and no effective therapeutic solution[6]

[1]https://alz-journals.onlinelibrary.wiley.com/doi/full/10.1002/alz.12450
[2]https://www.science.org/content/article/another-alzheimers-drug-flops-pivotal-clinical-trial
[3]https://www.biogen.com/en_us/ceo-letter-alzheimers-therapy.html
[4]https://www.nytimes.com/2022/06/16/health/alzheimers-drug-crenezumab.html
[5]https://www.scientificamerican.com/article/why-alzheimer-s-drugs-keep-failing/
[6]https://www.wsj.com/articles/lack-of-optimism-for-alzheimers-trials-means-theres-little-to-lose-11663121287

Progress? Not so fast.

Biogen & Eisai recently announced[1] that their drug Lecanemab appeared to slow down Alzheimer's

- Results come after the failure of the companies' drug Aducanumab
- Clinical trials based on outdated small molecule drugs strategy and too short a time frame
- Lecanemab is unlikely to produce a different disease outcome from the fatal one we see 100%
- Drug effect is to help suppress the symptoms, equivalent to using a cough suppressant to treat a virus infection such as the recent pandemic
- Alzheimer's and CNS is addressed by Telocyte with
  - next generation biologic clinical methods
  - superior gene therapy techniques with faster routes for clinical evaluation
  - reduced program cost and much shorter development timescales

Regrettably, Eisai recently published that Lecanemab has likely contributed to a patient's death[2]

[1]https://apnews.com/article/health-2e51397597577d49d6d5f82bc0042871
[2]https://www.fiercebiotech.com/biotech/lecanemab-may-have-contributed-patient-death-report

Telocyte Mission

Disrupt
global healthcare and the pharmaceutical industry with telomerase therapy

Reverse
age-related diseases starting with Alzheimer's

Deliver
preventative and therapeutic healthcare via AI and Big Data driven Virtual Diagnostic Clinics



Telocyte Disruption

Only biotech company addressing Alzheimer's and age-related diseases using the Telomerase protocol & AI Therapeutics

TELOMERASE INNOVATION

The first and only Human Telomerase Protocol to cure human age-related diseases

AI THERAPEUTICS

Ethical AI+VR: deliver a holistic therapeutic **precision preventative care**, and substantially **reduce clinical costs**

EXPERTISE

Telocyte is founded by **Dr. Michael Fossel, the world's leading expert on cellular aging and age-related diseases**

KNOWLEDGE PLATFORM

Telocyte's **innovative knowledge strategy** ensures effective, secure, and compliant clinical execution, as well as enabling the advent of digital similars in life sciences

Telomerase Origins

TELOCYTE
A FUTURE BEYOND ALZHEIMER'S

1974

Alexey Olovnikov[1]

First prediction of telomerase existence and link to aging and cancer

1981

Elizabeth Blackburn[2]

Isolates and describes the telomerase enzyme

1997

Michael Fossel[3]

First articles (in *JAMA*) on the potential to treat age-related disease with telomerase

1998

Calvin Harley

CSO, GERON[4,5,6]

Telomerase resets aging in human cells and tissues

2004



Michael Fossel

Clinical Medicine Expert, GERON[6,7]

Clinical telomerase protocol with Calvin Harley

2009

Blackburn, Greider, Szostak[8]

2009 Nobel Prize for the discovery of telomerase

2012

Maria Blasco[9]

Telomerase delays aging in mice

2020

Michael Fossel

Founder of Telocyte[10]

Telomerase protocol for age-related diseases



[1]https://en.wikipedia.org/wiki/Alexey_Olovnikov
[2]https://en.wikipedia.org/wiki/Elizabeth_Blackburn
[3]https://doi.org/10.1001/jama.1997.0355016006504
[4]https://pubmed.ncbi.nlm.nih.gov/9454332/
[5]https://pubmed.ncbi.nlm.nih.gov/11850774/
[6]https://pubmed.ncbi.nlm.nih.gov/12663456/
[7]https://jamanetwork.com/journals/jama/article-abstract/187604
[8]https://www.nobelprize.org/prizes/medicine/2009/summary/
[8]https://www.embopress.org/doi/full/10.1002/emmm.201200245
[9]https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/alz.12012

Telomerase Evolution

Telomerase Reverses Aging Animals

Telomerase Reverses Aging in Human Cells



Telomerase Reverses Aging in Human Tissues

Telocyte's Unique Human Telomerase Protocol to Reverse Aging in Patients

Validation in Animals

Telomerase is proven to reverse the aging process in animal studies, resulting in improved behavioral[1,2,3], musculoskeletal[2], and cardiovascular[2] function







[1]https://pubmed.ncbi.nlm.nih.gov/21211774/
[2]https://www.embopress.org/doi/full/10.1002/emmm.201200245
[3]https://doi.org/10.1038/nature09603

Validation in Human Cells/Tissues

Human cells

Fibroblasts[1]: *Science,* 1998

Neurons[2]: *J Neuroscience,* 2015



Human tissues

Skin[3]: *Exp Cell Res,* 2000

Bone[4]: *J Bone Mineral Res*, 2001

Cardiac Vessels[5]: *Circ Res*, 2001

Medical textbooks

- ***Cells, Aging, and Human Disease***

  Michael Fossel, 2004

- ***Aging:*** ***How aging works, how we can reverse aging, and prospects for curing aging diseases***

  Michael Fossel, 2023 (in preparation)



[1]https://www.science.org/doi/10.1126/science.279.5349.349
[2]https://www.jneurosci.org/content/35/4/1659
[3]https://pubmed.ncbi.nlm.nih.gov/10896778/
[4]https://pubmed.ncbi.nlm.nih.gov/11499868/
[5]https://doi.org/10.1161/hh2101.098443

Reverse Aging

Telocyte's proprietary telomerase-based protocol will reverse cell aging in humans, curing age-related diseases

As cells age, telomeres shorten and cells become dysfunctional, resulting in age-related diseases. The telomerase protocol restores a younger pattern of gene expression and normal cell function. Telocyte's solution brings telomerase to humans.

https://www.tasciences.com/telomeres-and-cellular-aging.html

Telocyte Products

Therapeutic

Proprietary telomerase-based protocol will reverse cell aging, curing age-related diseases



AI Therapeutics

- AI-enhanced diagnostics
- Alerting and signaling
- Personalized therapeutics
- Pre-treatment targeting
- Treatment outcome prediction

Knowledge Platform

- Blockchain, data provenance
- Built-in governance and compliance (HIPAA, OHRP, FDA)
- Identity, data ownership, dynamic consent
- Federated AI
- Support decentralized clinical trials

Telocyte Proprietary Protocol

The First and Only Human Telomerase Protocol

Dose: Adjusted to patient's body/brain weight

Route: Carefully chosen for safety & efficacy

Vector & Plasmid: Optimized to target cells

FDA Compliant[1]: Rigorous & credible

Human Protocol **FDA BLA compliant[1]**								
Study			Pretrial	Day 1	Week 1	Week 4	Month 2	Month 4	Month 6
Therapy	Treatment	TEL-01							
	Procedure	ICM injection							
Evaluation	Clinical	Interview							
		Physical Exam							
Trial Data	Cognitive	MMSE, ADAS-Cog, etc.							
	Laboratory	Misc. (UA)							
		Blood							
		CSF							
	Imaging	PET/MRI							

General targets

- All aging, dysfunctional cells



Specific targets

- **Alzheimer's** (CNS):
  - Neurons
  - Microglia
  - Astrocytes
- **Cardiovascular Disease**:
  - Vascular cells
  - Cardiac myocytes
  - Fibroblasts

[1]https://www.fda.gov/vaccines-blood-biologics/development-approval-process-cber/biologics-license-applications-bla-process-cber

Knowledge Platform

TELOCYTE
A FUTURE BEYOND ALZHEIMER'S

DATA AS AN ASSET

- Secure data exchange network and custody of user's digital assets
- Identity management and verification capabilities, dynamic consent
- Auditability and data provenance authentication via hybrid blockchain
- Data trust and quality persistence

COMPLIANCE

- Built-in governance and compliance for healthcare data (HIPAA, OHRP, FDA)
- Integration with EMRs, CROs, partners, and government platforms, 21 CFR 11 compatible



DATA SOURCE AND INTEGRATION

- Healthcare data (EHR, clinical)
- Biometrics data (real-time, historical)
- Lifestyle, contextual, and financial data
- Consumer, social, and impression data
- Daily data through VR interaction and capture

ANALYTICS & AI

- Therapeutic program personalization
- Digital similars
- Treatment outcome prediction
- AI for diagnostics, monitoring, virtual healthcare
- Derived data through federated AI for marketplace participation and services

PROGRAM SUPPORT

- Clinical decision support
- Accelerate therapeutic deployment
- Cost reduction through AI-based clinical optimization
- AI-enhanced therapeutic population targeting

CUSTOMER VALUE

- User engagement and loyalty through privacy and earned trust
- Therapeutic and lifestyle care using AI and VR platform
- Health assessment and monitoring for holistic and precision preventative care

Data Strategy

Traceability & Compliance

- Hybrid blockchain platform
- Operational data network
- Built-in compliance
- Access management and control
- Auditable API integration with clinical endpoints
- Indisputable record of clinical results



Personalization

- Hyper-personalization
- Granular consent
- Health knowledge platform
- Increased patient engagement and participation in trials and preventative care

Clinical Cost Reduction

- Data compliance and architecture yields over 30% cost reduction of expenses and time in clinical trial expenses, worth $ billions in later trial phases

Digital DNA

- Digital graph with trust and context built in captures all patient data, relationships, and events
- Multi-source data validation increases the quality and value of the data

AI Therapeutics & VR Clinic

TELOCYTE
A FUTURE BEYOND ALZHEIMER'S

Virtual Personalized Care

- Ethical AI+VR
- Personalized therapeutic program
- Preventative care, alerting
- Health assessment and outcome prediction via continuous learning

Extend Support Circle

- Remote patient monitoring reduces hospitalizations[1]
- Remote medication management
- Personal healthcare assistance
- Virtual visits

Trust and value

- HIPAA and FDA compliant
- Secure and safe
- Personalization
- Ethical and compliant AI

E-Learn & Engage

- Educate about age-related diseases and preventative care
- Information on decentralized clinical trials

[1]https://blog.amchealth.com/can-telemonitoring-reduce-hospitalization-and-cost-of-care-a-health-plans-experience-in-managing-patients-with-heart-failure

Endorsements for Telocyte

”Dr. Fossel’s unwavering dedication to unraveling the pathogenesis of neurodegenerative diseases led him to conceive both a unified model and a novel gene therapy with the potential to become the first agent to alter the course of neurodegenerative diseases such as Alzheimer’s.

Telocyte’s telomerase gene therapy will restore hope to Alzheimer’s disease patients. Applications to other neurodegenerative conditions such as Parkinson’s and age-related diseases (e.g., cardiovascular, renal, osteoarthritis) will follow.”

S. Nagendran MD

President of R&D and Chief Medical Officer, *Jaguar Gene Therapy*

”Dr. Fossel has set out a new model for dementia and age related brain dysfunction which presents a unifying theory [...] and potentially of an exciting new approach to disease causation and hence treatment.

His in-depth analysis is intellectually compelling and takes account of a wide range of experimental data from several fields. Dr. Fossel’s work presents radical new ideas and is extremely exciting.”

Sir Edward Byrne AC FmedSci FTSE FAHMS MD DSc FRCP FRACP

Vice Chancellor Monash University
President King’s College
Vice Chancellor’s Distinguished fellow ANU
Emeritus Professor of Neurology King’s College

“Dr. Fossel offers us a logical and potentially effective point of intervention for Parkinson’s, Alzheimer’s disease and other age-related neurodegenerative diseases. His model calls for clinical testing – rigorously and credibly – as his approach may well be the most promising approach that we have seen in decades.

I heartily and unreservedly recommend him for the Breakthrough Prize in Life Sciences.”

Z. Khachaturian PhD

President of *Campaign to Prevent Alzheimer’s*, former editor-in-chief *Alzheimer’s & Dementia, Journal of the Alzheimer’s Association*

Competitive Landscape

Companies are targeting the symptoms

β Amyloid



Eli Lilly
Biogen
Alzheon
Vivoryon
Wren Therapeutics
Yumanity
AC Immune SA
Denali Therapeutics
Priaboid

Tau

Voyager Therapeutics
AC Immune SA
Denali Therapeutics
Priaboid

Inflammation



TBD Therapeutics

Mitochondria



Alector
Amylyx Pharma
Codiak BioSciences
Oracion Biotech
Tetra

Telocyte is targeting the underlying cause

Telomerase

TELOCYTE

Market Opportunity

Central Nervous System

Alzheimer's

- global therapeutics market $4B in 2021
- growing at a CAGR of 16.2%
- **global costs $1.7 trillion by 2030[1]**

Parkinson's

- **global costs over $51B by 2030[2]**

Other Dementias

- **global MS costs $84B in 2030[3]**
- **other Dementia costs $800B by 2030[4]**

Cardiovascular Disease

- global CVD drug market: $48B
- projected to reach $64B by 2026
- growing at a CAGR of 3.8%
- **global costs to reach $1.0T by 2035**

Myocardial Infarction
Carotid Artery Disease
Congestive Heart Failure

Other

Osteoarthritis
Osteoporosis
Pulmonary fibrosis
Renal failure
Immunosenescence

[1]https://www.alzint.org/about/dementia-facts-figures/dementia-statistics/
[2]https://rdcu.be/cUFE0
[3]https://n.neurology.org/content/98/18/e1810
[4]https://www.rand.org/capabilities/solutions/planning-for-the-rising-costs-of-dementia.html

Strategy

OBJECTIVE

Telocyte brand dominance in age-related and preventative Healthcare

TARGET MARKET

Age-related disease, beginning with Alzheimer's (7M in US in 2028, 60M+ worldwide)

VALUE

An affordable and effective Telomerase Gene Therapy as a 5-yearly vaccination for Alzheimer's and age-related diseases

DISTRIBUTION

Licensing agreements with NHS and Big Pharma, covering the costs of servicing the Alzheimer's global population

PRICING

Initial pricing: 40% of the US 5-year patient cost of Alzheimer's, approx. $104,600/dose

REVENUE

$52B over the first 10 years through licensing (5% royalty)

INTEREST

NHS UK, Eli Lilly, Jiangsu Province, China, GemVax, South Korea

GROWTH

- Target population increase (2x-3x)
- VR Clinic + AI: increase SAM
- Distribution + AI: Increase Adoption

Revenue

Initial Price: $104,600/dose (40% of 5-year Alzheimer's cost/person)

Licensing Royalty: 5% of net sales

Target Population (TAM): 7M US, 50M globally, to grow 2x to 3x[2]

Serviceable Population (SAM): 10% of TAM initially



Year	TAM US AD	TAM World AD	SAM US	SAM World
2028	7,000,000	58,000,000	700,000	0
2029	7,750,000	63,000,000	2,976,000	0
2030	8,500,000	68,000,000	3,264,000	8,993,000
2031	9,250,000	73,000,000	3,552,000	14,481,375
2032	10,000,000	78,000,000	3,840,000	20,631,000
2033	10,750,000	83,000,000	4,128,000	27,441,875
2034	11,500,000	88,000,000	4,416,000	34,914,000
2035	12,250,000	93,000,000	4,704,000	43,047,375
2036	13,000,000	98,000,000	4,992,000	51,842,000
2037	13,750,000	103,000,000	5,280,000	61,297,875
2038	14,500,000	108,000,000	5,568,000	71,415,000

Year	SAM US	SAM World	Adoption US	Adoption World	Price	Royalty
2028	700,000	0	0.66%	0.00%	$104,600	5%
2029	2,976,000	0	1.48%	0.00%	$99,370	5%
2030	3,264,000	8,993,000	2.17%	0.66%	$94,140	5%
2031	3,552,000	14,481,375	2.86%	1.48%	$88,910	5%
2032	3,840,000	20,631,000	3.55%	2.17%	$83,680	5%
2033	4,128,000	27,441,875	4.24%	2.86%	$78,450	5%
2034	4,416,000	34,914,000	4.93%	3.55%	$73,220	5%
2035	4,704,000	43,047,375	5.62%	4.24%	$67,990	5%
2036	4,992,000	51,842,000	6.31%	4.93%	$62,760	5%
2037	5,280,000	61,297,875	7.00%	5.62%	$57,530	5%
2038	5,568,000	71,415,000	7.69%	6.31%	$52,300	5%

Revenue projections with Total Addressable Market (TAM), Service Addressable Market (SAM), and Adoption estimates[3]

[1]https://invivo.pharmaintelligence.informa.com/IV146643/Strategies-To-Encourage-Universal-Access-To-Gene-Therapies
[2]https://www.who.int/news-room/fact-sheets/detail/ageing-and-health
[3]https://www.alz.org/media/Documents/alzheimers-facts-and-figures.pdf

Gene Therapy Valuations

COMPANY	PURCHASER	DEAL VALUE	DRUG/TARGET
AveXis	Novartis	$8.7 billion	Zolgensma - Spinal Muscular Atrophy
Spark Therapeutics	Roche Holdings	$4.8 billion	Luxterna - Genetic Retinal Diseases
Audentes Therapeutics	Astellas Pharma	$3.0 billion	Neuromuscular Diseases
Brammer Bio	Thermo Fisher	$1.7 billion	Viral Vectors for Gene Therapy
AskBio	Bayer	$4.0 billion	Neuromuscular, CNS, and Others
Sarepta Therapeutics	Roche Holdings	$1.2 billion	Duchene Muscular Dystrophy, etc.
Paragon Bioservices	Catalent	$1.2 billion	AAV & Plasmids for Gene Therapy

The Journey

Partnerships

- Strategic partners for clinical trials: Houston Methodist
- Strategic partners for drug manufacturing and CRO services: Thermo Fisher
- Strategic partners for the build and operation of the data and technology platform
- Strategic partners for VR Clinic

Inception

- Founded in 2015 by Michael Fossel, MD, PhD, the leading expert on cell aging and age-related disease
- Seed investment of $600k

Team

- Strong management team
- Globally recognized scientists, clinicians, and gene therapy experts on Scientific & Clinical Advisory Boards adding rigor and global credibility in protocol design and execution
- Accomplished Business and technical advisors



Telocyte Program

Disrupt global healthcare and pharma with telomerase therapy

IP and Compliance

- Cleared legal/IP search
- Independent gap analysis by a global CRO confirmed readiness for FDA and regulatory trials
- Clinical trial protocol validated and peer-reviewed

Licensing Bidders

- Eli Lilly
- NHS UK
- GemVax
- Jiangsu Province, China

Multi Phased Roadmap

Completed:

- Formation and Proprietary Product
- Executive Team and Advisory Board
- Partnerships for Clinical Trials, Data Platform, Drug Manufacturing
- IP Search, FDA Compliance[1]

Cost Budget $1.0m + CXO invaluable hours

Objectives:

- Canine study
- Dosing, distribution, safety, & toxicity data
- Dev Knowledge Platform
- Dev AI Therapeutics
- Manufacturing and FDA feedback

Cost Budget $3.3m

Objectives:

- File for FDA Phase 1 human trial
- Manufacture of gene therapy product
- File IP on canine and human protocols (Cooley LLP)
- VR Clinic Prototype

Cost Budget $5.4m

Objectives:

- Begin FDA Phase 1 human trial
- Knowledge Platform
- Federated AI services
- AI Therapeutics Launch
- VR Clinic Beta

Cost Budget $4.7m

Objectives:

- Complete FDA Phase 1 human trial
- FDA Phase 2 human trial
- Increased valuation from proven human efficacy
- Launch VR clinic
- Enhanced Diagnostics

Cost Budget $3.7m

[1]https://www.fda.gov/vaccines-blood-biologics/development-approval-process-cber/biologics-license-applications-bla-process-cber

Next Steps

In partnership with Houston Methodist, a leading neurosciences clinical trial institution, to carry out simultaneous Telocyte CNS and CVD studies to permit human trials.

Canine study

Objective: obtain efficacy, distribution, and toxicity data

Protocol: Houston-based 6-month study of 12 aged dogs

Measures: imaging, labs, cognitive performance, etc.

https://www.houstonmethodist.org/

Human trials

Objective: obtain FDA safety and efficacy data in phase 1 trial

Protocol: US-based 6-month study of 12 patients with moderate Alzheimer's

Measures: imaging, labs, cognitive testing,etc.

Executive Team

TELOCYTE
A FUTURE BEYOND ALZHEIMER'S

Michael Fossel MD, PhD
Founder, CMO

The leader in proposing the use of telomerase to treat age-related human disease, he has an MD and PhD in Neurobiology from Stanford University, was a clinical professor of medicine for almost three decades, and authored both *The Telomerase Revolution* (which the *Wall Street Journal* named as one of the best science books of 2015) and the Oxford University Press textbook, *Cells, Aging, and Human Disease.*

Therapeutics

Peter Rayson
Founder, CEO

An experienced industry executive, Rayson provides leadership and business acumen for Telocyte. His background includes engineering management with Computer Vision Inc., as well as working with Rolls Royce Aerospace, Airbus, Ford, Jaguar Land Rover. He was the Associate Director of the Technology Innovation Center at Birmingham, UK but stepped down in 2011 when his mother was diagnosed with dementia.

Business

Rajesh Shukla, PhD
CSO

Rajesh brings over 30 years of entrepreneurial biotechnology expertise with clinical and medical strategy, with over $300M in funding. Rajesh leads gene therapy clinical development leveraging discovery through registrational expertise in Neurology, Immunology, Infectious Diseases, Oncology, Surgical reconstruction, Asthma and Anaphylaxis clinical programs, with senior positions at Integra LifeSciences, Castle Creek Biosciences (VP, R&D), Motif Biosciences (VP), Acorda therapeutics (Sr Medical Director), Pfizer (Sr Director & R&D Head), Teva and Bristol-Myers Squibb.

Drug Development

Michelle Hylan
COO

Michelle Hylan is an internationally experienced **Clinical Research Executive** with demonstrated success partnering with clients to optimize clinical program outcomes through alignment of business strategy, processes, and org composition, as well as bringing biotech start-ups from proof of concept to IPO. Michelle has focused on advancing unique science solutions to address unmet medical needs. She has broad experience in industry best practices on global program, clinical, and quality management. She specializes in strategic development and implementation, clinical trial design, CRO/vendor selection and management.

Clinical Operations

Georgi Gospodinov PhD
CTO

An executive, advisor, and investor, offering thought leadership and innovative ideas, Georgi has led the engineering and analytics teams of multiple enterprises to deliver strategic product vision, tech resource hire and management, enterprise security, architecture, and integration. He has managed product delivery and driven innovation in data and technology, directly contributing to the design and implementation of product.

Technology & AI

Radomir Julina, PhD
CPO

Prior to his current role as Managing General Partner at Pharma Capital Partners, Radomir was head of New Molecular Entity Planning at Roche and ran an Alzheimer's drug clinical trial through Phase III. He has worked in pharmaceutical, biotech and private equity for the last 25+ years. He was Managing Director at Celtic Pharma Management, a spin-off from Hoffmann-La Roche. He holds a Ph.D. in Organic Chemistry from the University of Zurich and has a passion for drug development, building virtual organizations and investment finance

Clinical Strategy

Board of Directors

Michael Fossel MD, PhD
Board Member

The leader in proposing the use of telomerase to treat age-related human disease, he has an MD and PhD in Neurobiology from Stanford University, was a clinical professor of medicine for almost three decades, and authored both *The Telomerase Revolution* (which the *Wall Street Journal* named as one of the best science books of 2015) and the Oxford University Press textbook, *Cells, Aging, and Human Disease.*

Therapeutics

Peter Rayson
Chairman of the Board

An experienced industry executive, Rayson provides leadership and business acumen for Telocyte. His background includes engineering management with Computer Vision Inc., as well as working with Rolls Royce Aerospace, Airbus, Ford, Jaguar Land Rover. He was the Associate Director of the Technology Innovation Center at Birmingham, UK but stepped down in 2011 when his mother was diagnosed with dementia.

Business

Mark Hodges
Board Member

An experienced technology executive, Hodges provides effective and inspiring leadership for all Telocyte programs and services. His background includes executive experience in the aerospace and defense industries, CAD business development, including at Computer Vision with Peter Rayson. He was the General Manager of China Operations, where he managed 500 engineers across 15 offices for PTC Inc., a listed Boston engineering software firm.

Operations

Technical Advisory Board

Professional expertise: gene therapy, telomerase, clinical trial design, and neurological disease

Mimoun Azzouz, PhD

The University Of Sheffield.

Joseph Araujo

InterVivo SOLUTIONS

Suzanne Hendrix, PhD

Pentara

Kurt Whittemore, PhD

Boston Children's Hospital

Mario Masellis, MD

Sunnybrook RESEARCH INSTITUTE

Steven Arnold, MD

HARVARD MEDICAL SCHOOL

Russell Swerdlow, MD

KU MEDICAL CENTER The University of Kansas

Strategic Investment & Partnership

Strategic investors:

- ❑ Invest $5M in Telocyte for supporting Phase 2 milestones
- ❑ Take care of Telocyte's clinical trials costs in return for equity
- ❑ Collaborate with Telocyte and take care of AI and Knowledge Platform development costs in return for equity
- ❑ Build and operate Telocyte business in India

Books Authored by Dr Michael Fossel









(in preparation)

A FUTURE BEYOND ALZHEIMER'S

www.telocyte.com